Antitrust is really here!

Centralized procurement of Chinese patent medicines is imminent, and the anti-monopoly cloud is coming again

Centralized procurement of Chinese patent medicines is imminent, and the anti-monopoly cloud is coming again

The anti-monopoly sword came out again

On August 30, at the 21st meeting of the Central Committee for Comprehensively Deepening Reform, the "Opinions on Strengthening Anti-Monopoly and Deepening the Implementation of Fair Competition Policy" deliberated and passed

Strengthening anti-monopoly and deepening the implementation of fair competition policies are the inherent requirements for improving the socialist market economy system

The pharmaceutical industry is a key area of ​​anti-monopoly this year

Since 2021, Simcere Pharmaceutical, Tianyao, and Yangzijiang Pharmaceutical have received huge fines due to monopoly

Under the new situation of increasing anti-monopoly noise, the road to control the sale of drugs will become narrower and narrower

Controlled sales model = monopoly

Controlled sales model = monopoly

Controlled sales is a sales model that pharmaceutical professionals are too familiar with.

Controlling sales also raised the price of medicines.

Controlling sales also raises the price of medicines.

The Harbin Pharmaceutical Sixth Factory, which was the first to get through the TV advertising sales code, was a master of sales control , while Sunflower Pharmaceutical, Amendment Pharmaceutical, and Renhe Pharmaceutical became the later three giants of pharmaceutical control and sales

The Harbin Pharmaceutical Sixth Factory, which was the first to get through the TV advertising sales code, was the three giants of pharmaceutical control and sales masters.

Another important task of controlling sales is to control online drug prices

In February 2021, Sichuan Meidakang Pharmaceutical stopped supplying several major e-commerce platforms because the online price of "Compound Pearl Mouth Granules" was three times lower than that of offline pharmacies

Sichuan Meidakang Pharmaceutical

Yangtze River's monopoly has been punished, which is regarded by the industry as a denial of the control and sales model of pharmaceutical companies

The industry sees it as a denial of the control and sales model of pharmaceutical companies

Where is the control of sales heading for the tightening of supervision?

Where is the control of sales heading for the tightening of supervision?

Anti-monopoly clearly says no to the control and sales of the pharmaceutical industry, and the industry is also changing its face and continuing to control sales

The "Internet Controlled Sales Model" came into being.

The country's first Internet controlled drug direct sales network

"Pharmaceutical contract" is the representative of the Internet controlled sales model

A large number of Internet sales control platforms such as Shengxing Pharmaceutical and Pharma Elf

This is obviously contrary to the general policy trend

In March this year, the China Chemical and Pharmaceutical Industry Association issued the "Pharmaceutical Industry Compliance Management Regulations", and anti-monopoly was highlighted

Anti-monopoly in the field of medicine, in the final analysis, is to reduce the price of medicines to protect the interests of patients

A series of policies such as centralized procurement, two-invoice system, medical insurance negotiation, anti-corruption, credit evaluation system, etc.
, all remind pharmaceutical companies that it is not feasible to follow the old road blindly
.

Just walking along the old road will not work

On August 9, the National Medical Insurance Administration made it clear in its response to the suggestion: The next step is to scientifically and steadily advance the reform of centralized procurement of proprietary Chinese medicines and formula particles, oriented to clinical demand, and start with high-priced and large-volume varieties
.
From the perspective of the industry, it is necessary to use antitrust and other means to reduce the market price of medicines before the development of centralized procurement of more varieties of Chinese patent medicines
.

Before the development of centralized procurement of more varieties of Chinese patent medicines, it is necessary to use antitrust and other means to reduce the market price of medicines.

The era of barbaric growth in the pharmaceutical industry is not over yet, but it will always pass
.